Clinical implications of prospective genomic profiling of metastatic breast cancer patients
Courtney T van Geelen, Peter Savas, Zhi Ling Teo, Stephen J Luen, Chen-Fang Weng, Yi-An Ko, Keilly S Kuykhoven, Franco Caramia, Roberto Salgado, Prudence A Francis, Sarah-Jane Dawson, Stephen B Fox, Andrew Fellowes, Sherene Loi
Breast Cancer Research | BMC | Published : 2020
BACKGROUND: Metastatic breast cancer remains incurable. Next-generation sequencing (NGS) offers the ability to identify actionable genomic alterations in tumours which may then be matched with targeted therapies, but the implementation and utility of this approach is not well defined for patients with metastatic breast cancer. METHODS: We recruited patients with advanced breast cancer of any subtype for prospective targeted NGS of their most recent tumour samples, using a panel of 108 breast cancer-specific genes. Genes were classified as actionable or non-actionable using the European Society of Medical Oncology Scale for Clinical Actionability of Molecular Targets (ESCAT) guidelines. RESUL..View full abstract
We thank the Breast Cancer Trials Group Australia and New Zealand for a seed grant that funded the main study as well as the Peter MacCallum Foundation Women's Health Initiative.PS was supported by the Royal Australian College of Physicians Shields Research Entry Scholarship, the NHMRC and NBCF co-funded post-graduate scholarship and Cancer Therapeutics CRC scholarship. SL is supported by the National Breast Cancer Foundation of Australia Endowed Chair and the Breast Cancer Research Foundation, New York.CVG is supported though an Australian Government Research Training Program (RTP) Scholarship.